NSE · Healthcare · updated 16 Oct 2026, 11:59 pm IST
Healthcare · NIFTY 50 · in NIFTY 50, NIFTY 100, NIFTY 200, NIFTY 500, NIFTY PHARMA, NIFTY HEALTHCARE · sector page
Sun Pharmaceutical Industries Ltd. trades on the NSE under the symbol SUNPHARMA and is classified under Healthcare (nifty 50 cap by NSE's index grouping). It is a constituent of NIFTY 50, NIFTY 100, NIFTY 200, NIFTY 500 and 2 other indices. NSE's securities master records its listing date as 8 Feb 1995.
On 16 Oct 2026 the stock closed at ₹1,758.8, -0.3% on the day. Over the past year it has traded between ₹1,563.3 and ₹2,001.1; the current price sits 45% of the way up that range, 12.1% below the 52-week high. The move has been -0.1% over five sessions, -4.3% over a month, -9.4% over three months, -2.7% over six months.
Volume in the last session was 0.9× the stock's 20-session average. 63% of that volume was taken as delivery, against a 20-session average of 64%.
No promoter or insider trades have been filed for the stock in the last 90 days. No bulk or block deals were disclosed in the last 30 days.
Among 13 Healthcare stocks tracked here, its one-month return ranks 7th; the strongest over the month was Cohance Lifesciences Ltd. (+6.0%).
| Face value | ₹1 |
| ISIN | INE044A01036 |
| 52-week range | ₹1,563.3 – ₹2,001.1 |
| 1-month return | -4.3% |
| 3-month return | -9.4% |
| 6-month return | -2.7% |
| Delivery (last session) | 63% (avg 64%) |
| Insider filings (90d) | 0 buy / 0 sell |
| Disclosed deals (30d) | 0 buy / 0 sell |
Max Healthcare Institute Ltd. -19.4% · Biocon Ltd. -9.3% · Piramal Pharma Ltd. -5.0% · Fortis Healthcare Ltd. -16.9% · Viyash Scientific Ltd. -9.5% · Dr. Reddy's Laboratories Ltd. +4.1% · Marksans Pharma Ltd. -2.9% · Zydus Lifesciences Ltd. -3.2% · Laurus Labs Ltd. +5.4% · Aster DM Quality Care Ltd. -10.7% · all Healthcare stocks
The US is the largest single export market for Indian drugmakers. Most of what they ship there is generics, and the Commerce Department said generics and their ingredients fall outside the Section 232 tariff. That…
The purchase roughly doubles Sun Pharma's revenue base and deepens its exposure to the US and biosimilars, but it is financed largely with $9.25-9.75 billion of new borrowing, so integration, synergy delivery and debt…
After a week with one small new issue, October's fundraising depends almost entirely on Jio Platforms, whose reported size is about twenty times that of Paras Healthcare. In Tonbo Imaging's case all proceeds go to…
Close price
Delivery % · 30-session average 65%
Delivery is the share of traded volume actually settled into demat accounts rather than squared off intraday — the difference between accumulation and churn. How it is used.
Exchange-disclosed transactions, reported as published.
| Date | Client | Type | Qty | Price | Value |
|---|---|---|---|---|---|
| No deals disclosed. | |||||